CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands		Convertible Preferred Stock Series A Convertible Preferred Stock	Convertible Preferred Stock Series B Convertible Preferred Stock	Convertible Preferred Stock Series C Convertible Preferred Stock	Convertible Preferred Stock	Common Stock		Additional Paid-in Capital Series A Convertible Preferred Stock	Additional Paid-in Capital Series B Convertible Preferred Stock	Additional Paid-in Capital Series C Convertible Preferred Stock	Additional Paid-in Capital	Accumulated other comprehensive income (loss )	Accumulated Deficit Series A Convertible Preferred Stock	Accumulated Deficit Series B Convertible Preferred Stock	Accumulated Deficit Series C Convertible Preferred Stock	Accumulated Deficit	Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Series C Convertible Preferred Stock	Total
Beginning balance at Dec. 31, 2019					$ 411,275											$ (422,862)				$ (422,862)
Beginning balance, shares at Dec. 31, 2019					318,510,205	7,787,470	[1]
Net income																(36,944)				(36,944)
Preferred stock dividend		$ 22,780	$ 777	$ 3,347				$ (1,048)	$ 1				$ (21,732)	$ (778)	$ (3,347)		$ (22,780)	$ (777)	$ (3,347)
Preferred stock accretion		$ 5,562	$ 53	$ 921				$ (3,572)	$ (37)	$ (563)			$ (1,990)	$ (16)	$ (359)		$ (5,562)	$ (53)	$ (922)
Issuance of common stock											$ 135,435									135,435
Issuance of common stock, Shares	[1]					6,151,162
Issuance of Series A, B, C convertible stock to common stock					$ (444,715)	$ 1					444,715									444,716
Issuance of Series A, B, C convertible stock to common stock, Shares					(318,510,205)	42,926,630	[1]
Reclassification of warrant liability to equity											5,468									5,468
Exercise of stock options											299									299
Exercise of stock options, Shares	[1]					37,947
Stock-based compensation											4,693									4,693
Repurchase and cancellation of common units																(167)				(167)
Repurchase and cancellation of common shares, Shares	[1]					(12,175)
Repurchase and cancellation of common units withheld for taxes											(17)									(17)
Repurchase and cancellation of common units withheld for taxes, Shares	[1]					(465)
Ending balance at Dec. 31, 2020						$ 1					585,374					(488,195)				97,180
Ending balance, shares at Dec. 31, 2020	[1]					56,890,569
Net income																34,597				34,597
Issuance of common stock											29,700									29,700
Issuance of common stock, Shares	[1]					1,270,462
Exercise of stock options											9,371									9,371
Exercise of stock options, Shares	[1]					664,738
Stock-based compensation											15,659									15,659
Ending balance at Dec. 31, 2021						$ 1					640,104					(453,598)				186,507
Ending balance, shares at Dec. 31, 2021	[1]					58,825,769
Net income																181,468				181,468
Unrealized loss on investments												$ (151)								(151)
Issuance of common stock											408									408
Issuance of common stock, Shares	[1]					8,050
Exercise of stock options											8,433									$ 8,433
Exercise of stock options, Shares						781,912	[1]													761,414
Stock-based compensation											26,173									$ 26,173
Ending balance at Dec. 31, 2022						$ 1					$ 675,118	$ (151)				$ (272,130)				$ 402,838
Ending balance, shares at Dec. 31, 2022	[1]					59,615,731

[1] Common stock of Harmony Biosciences Holdings, Inc.